Roswell Park Comprehensive Cancer Center investigators will deliver 21 presentations at the AHNS 12th International Conference on Head and Neck Cancer.
|Videos|August 3, 2017
Dr. Bauml Discusses Immunotherapy Agents in Head and Neck Cancer
Author(s)Joshua Bauml, MD
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy agents in head and neck cancer.
Advertisement
Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy agents in head and neck cancer.
Advertisement
Related to this article
Trastuzumab deruxtecan did not meet the prespecified efficacy criterion in HER2-low salivary gland carcinoma, though responses were observed in salivary duct carcinoma.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
The FDA approved selpercatinib for RET fusion–positive advanced solid tumors.
Neoadjuvant and adjuvant pembrolizumab improved EFS across surgical outcome subgroups in resectable head and neck squamous cell carcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
5